Dave Maraldo, Ph.D., president of manufacturing at Merck, explains how flexible capacity, earlier input from manufacturing in R&D, and digital tools are helping the organization keep up with a faster, more varied portfolio.
Feature|Articles|October 8, 2026
Before You Sign with a New Hub Vendor, Ask These Four Questions
Author(s)Douglas Bock
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient support program vendor.
Advertisement
Advertisement
Hub vendor transitions are accelerating. A 2026 Cardinal Health survey of 200 biopharma executives found that 45% are considering consolidating hub vendors by 2028, and 39% have felt pressure to move hub functions in-house, up from 28% in 2024.
Related to this article
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
Gilead agrees to acquire an oral IL-23R inhibitor from PepStar, while Zymeworks licenses its DLL3-targeting T cell engager ZW209 to Roche.
Incubate’s John Stanford on why MFN is voluntary in name only — and why the moonshot is the first casualty of drug pricing pressure.
Deborah Waterhouse is leaving ViiV Healthcare to become CEO and managing director of CSL.
Merck KGaA, Darmstadt, Germany, agrees to acquire Silence Therapeutics for roughly $1.3 billion, gaining a siRNA asset, divesiran.
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
Advertisement
Advertisement